The evolving Use of prognostic factors after resection of colorectal liver metastases

Georgios Karagkounis, Michael A. Choti

Research output: Contribution to journalArticle

Abstract

The expanding use of surgical therapy for patients with colorectal liver metastases (CRLM) and developments in chemotherapeutic regimens have led to a significant improvement in survival. However, outcomes can vary substantially and criteria for determining the prognosis of individual patients are lacking. Traditionally, clinicopathologic factors, for example primary tumor stage, number and size of liver metastases, preoperative carcinoembryonic antigen levels, presence of extrahepatic disease, and others, have been used to determine which patients are more likely to experience recurrence and poor survival. However, these factors, both separately and as part of scoring systems, have been inconsistent and conflicting in determining prognosis. Recently, molecular and biological indicators have emerged as potential prognosticators for CRLM patients undergoing hepatic resection. Tumor response to chemotherapy, both on imaging and on pathology, mutation status of such oncogenes as KRAS and BRAF, and expression patterns of proliferative markers including MACC1 and Ki-67, have all furnished promising results in prediction of patient outcomes. Moreover, circulating tumor cells and tumor DNA may not only be a useful prognostic instrument but also an excellent means of screening for early detection of recurrence.

Original languageEnglish (US)
Pages (from-to)218-226
Number of pages9
JournalCurrent Colorectal Cancer Reports
Volume10
Issue number2
DOIs
StatePublished - 2014

Fingerprint

Neoplasm Metastasis
Liver
Circulating Neoplastic Cells
Recurrence
Neoplasms
Survival
Carcinoembryonic Antigen
Oncogenes
Pathology
Drug Therapy
Mutation
DNA
Therapeutics

Keywords

  • BRAF
  • Colorectal liver metastases
  • Hepatectomy
  • KRAS
  • Molecular
  • Prognostic factors
  • Resection
  • Scoring systems
  • Survival

ASJC Scopus subject areas

  • Oncology
  • Gastroenterology
  • Hepatology

Cite this

The evolving Use of prognostic factors after resection of colorectal liver metastases. / Karagkounis, Georgios; Choti, Michael A.

In: Current Colorectal Cancer Reports, Vol. 10, No. 2, 2014, p. 218-226.

Research output: Contribution to journalArticle

Karagkounis, Georgios ; Choti, Michael A. / The evolving Use of prognostic factors after resection of colorectal liver metastases. In: Current Colorectal Cancer Reports. 2014 ; Vol. 10, No. 2. pp. 218-226.
@article{012539c7813e4951a8c3e081b83831c7,
title = "The evolving Use of prognostic factors after resection of colorectal liver metastases",
abstract = "The expanding use of surgical therapy for patients with colorectal liver metastases (CRLM) and developments in chemotherapeutic regimens have led to a significant improvement in survival. However, outcomes can vary substantially and criteria for determining the prognosis of individual patients are lacking. Traditionally, clinicopathologic factors, for example primary tumor stage, number and size of liver metastases, preoperative carcinoembryonic antigen levels, presence of extrahepatic disease, and others, have been used to determine which patients are more likely to experience recurrence and poor survival. However, these factors, both separately and as part of scoring systems, have been inconsistent and conflicting in determining prognosis. Recently, molecular and biological indicators have emerged as potential prognosticators for CRLM patients undergoing hepatic resection. Tumor response to chemotherapy, both on imaging and on pathology, mutation status of such oncogenes as KRAS and BRAF, and expression patterns of proliferative markers including MACC1 and Ki-67, have all furnished promising results in prediction of patient outcomes. Moreover, circulating tumor cells and tumor DNA may not only be a useful prognostic instrument but also an excellent means of screening for early detection of recurrence.",
keywords = "BRAF, Colorectal liver metastases, Hepatectomy, KRAS, Molecular, Prognostic factors, Resection, Scoring systems, Survival",
author = "Georgios Karagkounis and Choti, {Michael A.}",
year = "2014",
doi = "10.1007/s11888-014-0220-y",
language = "English (US)",
volume = "10",
pages = "218--226",
journal = "Current Colorectal Cancer Reports",
issn = "1556-3790",
publisher = "Springer Science + Business Media",
number = "2",

}

TY - JOUR

T1 - The evolving Use of prognostic factors after resection of colorectal liver metastases

AU - Karagkounis, Georgios

AU - Choti, Michael A.

PY - 2014

Y1 - 2014

N2 - The expanding use of surgical therapy for patients with colorectal liver metastases (CRLM) and developments in chemotherapeutic regimens have led to a significant improvement in survival. However, outcomes can vary substantially and criteria for determining the prognosis of individual patients are lacking. Traditionally, clinicopathologic factors, for example primary tumor stage, number and size of liver metastases, preoperative carcinoembryonic antigen levels, presence of extrahepatic disease, and others, have been used to determine which patients are more likely to experience recurrence and poor survival. However, these factors, both separately and as part of scoring systems, have been inconsistent and conflicting in determining prognosis. Recently, molecular and biological indicators have emerged as potential prognosticators for CRLM patients undergoing hepatic resection. Tumor response to chemotherapy, both on imaging and on pathology, mutation status of such oncogenes as KRAS and BRAF, and expression patterns of proliferative markers including MACC1 and Ki-67, have all furnished promising results in prediction of patient outcomes. Moreover, circulating tumor cells and tumor DNA may not only be a useful prognostic instrument but also an excellent means of screening for early detection of recurrence.

AB - The expanding use of surgical therapy for patients with colorectal liver metastases (CRLM) and developments in chemotherapeutic regimens have led to a significant improvement in survival. However, outcomes can vary substantially and criteria for determining the prognosis of individual patients are lacking. Traditionally, clinicopathologic factors, for example primary tumor stage, number and size of liver metastases, preoperative carcinoembryonic antigen levels, presence of extrahepatic disease, and others, have been used to determine which patients are more likely to experience recurrence and poor survival. However, these factors, both separately and as part of scoring systems, have been inconsistent and conflicting in determining prognosis. Recently, molecular and biological indicators have emerged as potential prognosticators for CRLM patients undergoing hepatic resection. Tumor response to chemotherapy, both on imaging and on pathology, mutation status of such oncogenes as KRAS and BRAF, and expression patterns of proliferative markers including MACC1 and Ki-67, have all furnished promising results in prediction of patient outcomes. Moreover, circulating tumor cells and tumor DNA may not only be a useful prognostic instrument but also an excellent means of screening for early detection of recurrence.

KW - BRAF

KW - Colorectal liver metastases

KW - Hepatectomy

KW - KRAS

KW - Molecular

KW - Prognostic factors

KW - Resection

KW - Scoring systems

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=84903718056&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903718056&partnerID=8YFLogxK

U2 - 10.1007/s11888-014-0220-y

DO - 10.1007/s11888-014-0220-y

M3 - Article

AN - SCOPUS:84903718056

VL - 10

SP - 218

EP - 226

JO - Current Colorectal Cancer Reports

JF - Current Colorectal Cancer Reports

SN - 1556-3790

IS - 2

ER -